ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1046
0,00%
Bitcoin
66.898,25
-0,27%
Brent Oil
83,76
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Allarity Therapeutics Inc (ALLR)

  7. Allarity Therapeutics Inc (ALLR) Notícias

ALLR

Allarity Therapeutics (ALLR)

Allarity Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALLR
DataHoraFonteTítuloCódigoCompanhia
17/05/202417:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
15/05/202410:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
14/05/202417:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLRAllarity Therapeutics Inc
14/05/202417:01GlobeNewswire Inc.Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity BalancesNASDAQ:ALLRAllarity Therapeutics Inc
08/05/202417:05Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:ALLRAllarity Therapeutics Inc
07/05/202410:30GlobeNewswire Inc.Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common StockNASDAQ:ALLRAllarity Therapeutics Inc
06/05/202409:00GlobeNewswire Inc.Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1NASDAQ:ALLRAllarity Therapeutics Inc
02/05/202409:00GlobeNewswire Inc.Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
29/04/202408:00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementNASDAQ:ALLRAllarity Therapeutics Inc
17/04/202410:10GlobeNewswire Inc.Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)NASDAQ:ALLRAllarity Therapeutics Inc
04/04/202410:15GlobeNewswire Inc.Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitNASDAQ:ALLRAllarity Therapeutics Inc
27/03/202409:30GlobeNewswire Inc.Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
25/03/202408:30GlobeNewswire Inc.Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)NASDAQ:ALLRAllarity Therapeutics Inc
08/03/202409:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALLRAllarity Therapeutics Inc
08/03/202409:15GlobeNewswire Inc.Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:ALLRAllarity Therapeutics Inc
07/03/202423:45Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALLRAllarity Therapeutics Inc
28/02/202408:00GlobeNewswire Inc.Allarity Therapeutics to Present at Biomarkers 2024NASDAQ:ALLRAllarity Therapeutics Inc
23/02/202418:09Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:ALLRAllarity Therapeutics Inc
02/02/202419:03Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ALLRAllarity Therapeutics Inc
26/01/202419:07Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALLRAllarity Therapeutics Inc
15/12/202319:00Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ALLRAllarity Therapeutics Inc
12/12/202308:00GlobeNewswire Inc.Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive AdvisorNASDAQ:ALLRAllarity Therapeutics Inc
05/12/202309:30GlobeNewswire Inc.Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion DiagnosticNASDAQ:ALLRAllarity Therapeutics Inc
30/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALLRAllarity Therapeutics Inc
02/11/202318:00Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLRAllarity Therapeutics Inc
31/10/202310:30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ALLRAllarity Therapeutics Inc
23/10/202318:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ALLRAllarity Therapeutics Inc
17/10/202318:00Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ALLRAllarity Therapeutics Inc
02/10/202308:00GlobeNewswire Inc.Allarity Therapeutics to Present at Biomarkers Europe 2023NASDAQ:ALLRAllarity Therapeutics Inc
30/08/202317:05GlobeNewswire Inc.PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for DovitinibNASDAQ:ALLRAllarity Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALLR

Seu Histórico Recente

EU
V532S
V532S
NASDAQ
POSKX
COIN
PDEXGBP
Polkadex
UNSW
XSPETH
XSwap
BOV
ITUBF323
ITUBF323 Ex:31
BIT
XZEM
Xtrackers MSCI EMG Mkts ...
UNSW
YFPROETH
YFPRO.FINANCE
BIT
UB3CVH
Unicredit Bank
BIT
FU0I5S
Vontobel
LBNK
SHIBDOGEUSDT
ShibaDoge
KUCN
HPBETH
High-Performance Blockchain
ASX
OXT
Orexplore Technologies
BIT
UC8T3M
Unicredit Bank
BIT
UC6THD
Unicredit Bank
AMEX
FLIA
Franklin International A...
EU
V227S
V227S
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados